We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Its Approach to Postmarket Studies and Clinical Trials
FDA Clarifies Its Approach to Postmarket Studies and Clinical Trials
In a draft revision of an April 2011 guidance, the FDA has laid out its current thinking on when the agency may require postmarket studies or clinical trials for approved prescription drugs.